Health analytics

Oncology

Oncology is one of the most dynamic and competitive areas for new therapeutics, with evolving endpoints, biomarker-driven subgroups, and rapidly shifting standards of care, all of which complicate route to reimbursement and market access.

It also places a significant burden on patients and healthcare systems; according to the Global Cancer Observatory by 2050, the number of new cancer cases per year is expected to rise by 33 million and the number of cancer-related deaths to 18.2 million. Success demands evidence that is not only scientifically robust but also aligned with payer priorities.

Health analytics Real world evidence generation Life sciences

LCP Health Analytics partners with COTA to advance the use of US RWD to support HTA decision making internationally

30 July 2025

LCP Health Analytics is partnering with COTA to explore how US real-world data can support health technology assessments (HTA) in the UK and EU.

Read now

At LCP Health Analytics, we combine advanced real-world data analytics with clinical and market access expertise to support oncology innovation

Evidence and strategy to unlock value in oncology

Oncology is a uniquely demanding therapeutic area in practice. Companion diagnostics, precision medicine, surrogate endpoints, data uncertainty and high-cost therapies introduce new layers of complexity, while payers and HTA bodies apply increasingly rigorous evidence standards. Generating credible, decision-ready insights in this space requires innovative methods, robust analytics, and clear value communication.

What sets us apart is our ability to bridge the gap between clinical and commercial – bringing together deep analytical capability, medical expertise and market access strategy. We don’t just deliver studies; we deliver decision-ready evidence and market insights that support the development of compelling value narratives that enable oncology medicines to reach patients most in need. We are committed to methodological innovation and excellence as highlighted in our contributions to ENCePP standards and supporting NICE in updating its framework on external validity and transportability methods.

Turning oncology data into payer-ready value

We provide end-to-end expertise across the innovation life cycle in evidence generation, real-world analytics, health economics, and market access strategy, helping our clients address their global evidence and strategy gaps:

Understanding disease and patient populations

Epidemiology, disease burden and care pathway mapping to size markets, inform eligible target populations, and identify unmet need.

Designing and executing real-world studies

Retrospective cohorts, registry analyses and target trial emulation, with transparent methods to address bias and confounding. Data landscaping and recommendations to support informed decision making regarding study viability.

Building external comparators

Robust control arms for single-arm trials and label expansions, using propensity methods and indirect comparisons.

Synthesising the evidence base

Targeted and systematic reviews, meta-analyses and indirect comparisons to define the totality of evidence.

Assessing outcomes and value

Real-world survival and other key endpoints, healthcare utilisation, cost analyses, and patient-reported outcomes (PROs/HRQoL), translated into actionable insights for HTA and payers.

Post-approval RWE including drug safety studies

Post-authorisation safety studies and comparative effectiveness.

Demonstrating economic value

Assessment of cost-effectiveness and budget impact, with methods tailored to the treatment’s indication and positioning.

Broader value modelling

Consideration of value beyond the healthcare system, such as impacts on patient productivity, caregiver burden, and health equity.

Market access and value strategy

Integrated early and throughout product lifecycle commercial planning, value proposition development, communication strategies, channel design as well as patient services tailored to oncology payer challenges.

Innovative reimbursement models

Scenario planning and design of outcomes-based agreements for high-cost oncology treatments.

HTA readiness

JCA strategy, PICO scoping, and alignment of study design with payer and regulatory expectations.

Policy shaping

Articulating the broader narrative around the importance of access for oncology medicines.

Our experts

View all experts

Explore our range of services

Real world evidence generation

We will work closely with you to navigate and address the increasingly complex need for rigorous and impactful real world evidence.

Find out more
Health economic outcomes research

We are passionate about helping you robustly evaluate and communicate the value of your product.

Find out more
Global market access strategy

Our strategic services help clients to navigate uncertainties and maximise value throughout the product lifecycle.

Find out more
US access solutions

We deliver value-based, evidence-driven solutions through deep clinical insight and strategic consulting.

Find out more
Medical and public affairs

We empower medical and public affairs teams to identify and act on opportunities for health system transformation.

Find out more